A previously announced public offering has been upsized by GenMark Diagnostics to offer about 6.4 million shares of its common stock and raise approximately $75 million in gross proceeds. The company, which has granted a 30-day option for the underwriters to buy up to 957,446 additional shares, plans to use the net proceeds for its commercialization efforts and general corporate functions.
Upsized offering could bring in $75M for GenMark Diagnostics
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.